NEUSTAR
Small-scale Distributed Denial of Service (DDoS) attacks are becoming more frequent and sophisticated, according to new research from Neustar ’s Security Operations Centre (SOC). Released today, the Q2, 2019 Cyber Threats and Trends report reveals that between April and June of this year, over 75 percent of all attacks mitigated by Neustar were 5 Gigabits per second (Gbps) or less, while large attacks – those of 100 Gbps and over – decreased by 64 percent.
At first glance, the evolution of DDoS attacks on enterprises seems to follow a pattern. The overall number of attacks during Q2 2019 compared with the previous year grew by 133 percent, which, though down from last quarter’s 200% growth, is still high. Stepping outside an analysis of the numbers of attacks to their composition, however, shows some interesting changes, according to Neustar.
Small and secretive
DDoS attacks have long been considered overwhelming threats and are traditionally associated with high rates of traffic. Such attacks do continue to take place, but smaller and more carefully targeted incursions are growing in quantity, intensity and duration. Such attacks do not seek to saturate the network link – and draw unwanted attention in the process – but to degrade or disable specific infrastructure within the target. Such lower volume incursions may enable the perpetrator to get in and get out unnoticed, or allow the attack to continue for quite a long time undetected. In fact, the longest duration for a single attack in Q2 was nearly two days.
These small attacks pose a significant threat, as they fall below the typical threshold that enterprises with a “detect and alert” DDoS mitigation strategy might employ. An attacker could therefore affect targets ranging from infrastructure to individual servers with relative impunity.
The situation becomes more alarming when considering an enterprise’s ability to recognise such threats when they were underway. When asked how likely they would be to notice today’s most prevalent smaller attacks, a staggering 72 percent of CTOs, CISOs and Directors of Security from the Neustar International Security Council (NISC) answered very unlikely, somewhat unlikely or somewhat likely. The remaining 28 percent of respondents felt it was very likely that they would notice a small-scale DDoS attack.
“With the rise of smaller DDoS attacks going under the radar, now is the time for organisations to deploy an ‘always on’ DDoS mitigation service that is constantly monitoring traffic to ensure threats of all sizes are detected, managed and diffused,” said Rodney Joffe, Senior Vice President, Senior Technologist and Fellow at Neustar.
“Now, with most of today’s attacks directed at specific services, gateways and applications – therefore requiring less traffic to bring it down – a greater level of understanding from businesses to determine the protection they need is essential. The first stage of this is to determine what is valuable, not what is vulnerable. One of the best ways to separate vulnerability from value is to create a ‘risk register’ that starts from the inside and focuses on your most critical business assets,” Joffe added.
A complimentary copy of The Neustar Q2’19 Cyber Threats and Trends Report is available here .
- ENDS -
About Neustar, Inc.
Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005036/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom